Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M

Dermata Therapeutics, Inc.

Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.
Cash and equivalents of $6.1M at Sep 30, 2024; expected to fund operations into Q2 2025.
Raised $7.8M in gross proceeds during 2024, including $5.1M in Q3 2024.
R&D expenses $2.4M in Q3 2024, up from $0.9M due to STAR-1 clinical trial costs.
G&A expenses $0.8M in Q3 2024, down from $0.9M in Q3 2023 on lower insurance costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.